Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (291-300 of 320) with videos related to

Pageof 32
Sort By:
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Atherosclerosis|January 29, 2014
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular diseaseHelena Gylling, Jogchum Plat, Stephen Turley, et al.
European Heart Journal|August 28, 2016
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Revista Espanola De Cardiologia (English Ed.)|February 2, 2018
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Diabetes|September 25, 2014
Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesityEric Frisdal, Soazig Le Lay, Henri Hooton, et al.
The Lancet. Child & Adolescent Health|July 24, 2020
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trialJonathan O'B Hourihane, Kirsten Beyer, Allyah Abbas, et al.
Pageof 32

Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Atherosclerosis|January 29, 2014
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular diseaseHelena Gylling, Jogchum Plat, Stephen Turley, et al.
European Heart Journal|August 28, 2016
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Revista Espanola De Cardiologia (English Ed.)|February 2, 2018
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L Catapano, Ian Graham, Guy De Backer, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
European Heart Journal|September 11, 2019
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskFrançois Mach, Colin Baigent, Alberico L Catapano, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Diabetes|September 25, 2014
Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesityEric Frisdal, Soazig Le Lay, Henri Hooton, et al.
The Lancet. Child & Adolescent Health|July 24, 2020
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trialJonathan O'B Hourihane, Kirsten Beyer, Allyah Abbas, et al.
Pageof 32